Genetic Cancer Tests
Precision oncology testing to identify the most effective drug treatment for cancer patients.
DNA genetic health screening tests to check for cancer predisposition.
Oncomine Comprehensive Plus Assay
The Oncomine™ Comprehensive Assay Plus is a targeted, next-generation sequencing (NGS) assay that provides a comprehensive genomic profiling solution appropriate for formalin-fixed paraffin-embedded (FFPE) tissues. The assay allows concurrent analysis of DNA and RNA to simultaneously detect multiple biomarkers associated with targeted and immune checkpoint research, including comprehensive targets that are relevant in cancer, in a single workflow. The Oncomine Comprehensive Assay Plus covers over 500 unique genes, including key cancer driver genes such as EGFR, BRAF, KRAS, ERBB2, and MET, fusions involving ALK, ROS1, RET, and NTRK1/2/3, and more.
Match Your Cancer with the Right Targeted Therapy
What are targeted therapies (IMAGE)
Targeted therapies are drugs that kill cancer cells but do not affect normal cells compared with chemotherapy which kills cancer and healthy cells.
Targeted cancer therapies are the form of personalised medicine that uses information about a person’s DNA profile to help treat your cancer.
Targeted therapy vs chemotherapy
Targeted therapies are much more effective than chemotherapy because they are designed to
- Specifically hit the target mutations present only in cancer cells
- Normal cells are unaffected by the treatment
- Toxic side effects are minimised
Every person’s cancer is unique
Every person’s tumour is unique because each person acquires different cancer DNA mutations during development of their disease. Today there are approx. 700 drugs which target each of these DNA mutation types.
